Analysts Issue Forecasts for Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Prothena in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the biotechnology company will post earnings of ($3.97) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share.

Other equities analysts have also issued research reports about the company. Bank of America lowered their price target on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $48.00 price objective (down from $84.00) on shares of Prothena in a report on Friday, December 20th. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Finally, Chardan Capital began coverage on Prothena in a research note on Friday, December 20th. They issued a “buy” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Prothena Stock Performance

Shares of PRTA opened at $14.43 on Wednesday. The firm’s 50-day simple moving average is $14.29 and its two-hundred day simple moving average is $18.02. Prothena has a fifty-two week low of $11.70 and a fifty-two week high of $34.65. The stock has a market cap of $776.48 million, a PE ratio of -5.82 and a beta of 0.10.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.08. The business had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The business’s revenue was down 98.9% on a year-over-year basis. During the same quarter last year, the business posted $0.38 EPS.

Institutional Trading of Prothena

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRTA. China Universal Asset Management Co. Ltd. boosted its position in shares of Prothena by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 4,026 shares during the period. Intech Investment Management LLC purchased a new position in Prothena during the 3rd quarter valued at $210,000. XTX Topco Ltd purchased a new position in Prothena during the 3rd quarter valued at $260,000. Orion Portfolio Solutions LLC grew its position in Prothena by 4.4% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock valued at $293,000 after acquiring an additional 739 shares during the last quarter. Finally, Creative Planning purchased a new stake in Prothena in the third quarter worth $350,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.